Navigation Links
Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Date:4/24/2009

SEATTLE, April 24 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the American Urological Association's (AUA) Annual Meeting in Chicago, as well as a Dendreon-sponsored IMPACT data webcast conference call:

  • April 28, 2009, 2:20 p.m. CDT - "A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC)." AUA Late-Breaking Science Forum to be held from 1:00 p.m. to 2:30 p.m. CDT. Room W375 at McCormick Place
  • April 28, 2009, 10:30 a.m. to 12:30 p.m. CDT - Abstract #1408: "Preclinical Evaluation of the TRPM8 Ion Channel Agonist D-3263 for Benign Prostatic Hyperplasia." Poster presentation to occur in the Benign Prostatic Hyperplasia: Basic Research session. Room W375B at McCormick Place
  • April 28, 2009, 4:30 p.m. CDT - IMPACT data webcast conference call

The IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study evaluated PROVENGE(R) (sipuleucel-T), Dendreon's investigational product candidate for men with advanced prostate cancer representing the first in a new class of active cellular immunotherapies specifically designed to engage the patient's own immune system against cancer. Dendreon announced last week that the IMPACT trial met its primary endpoint of improving overall survival compared to a placebo control.

To access the live conference call, dial 1-877-675-4753 (domestic) or 719-325-4864 (international). The call also will be audio webcast and will be available from the Company's website at www.dendreon.com under the "Investor/Webcast
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
2. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
3. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
4. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
5. Dendreon Reports Third Quarter 2008 Financial Results
6. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
7. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
8. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
9. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
10. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
11. Dendreon Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015  Metanome, Inc., an ... the company has changed its name to Diversigen, ... positioning as the single commercial source for the ... capitalize on the diverse opportunities of the microbiome. ... Diversigen accepts – including those that are difficult ...
(Date:4/23/2015)... 2015 Delpor, Inc. (Delpor), a biotechnology ... United States Patent and Trademark Office has issued 2 ... technology. US Pat. No. 8,986,727 was issued on ... delivery device for the sustained release of therapeutic ... the sustained (zero-order) release of large and small molecules ...
(Date:4/22/2015)... April 22, 2015   MPIRICA Health Inc. ... $1.6M in Series A financing from the McQuinn ... helps accelerate consumer and employer awareness of MPIRICA.com, ... at over 4,800 U.S. hospitals. "As ... probably very concerned about choosing the hospital and ...
(Date:4/22/2015)... (PRWEB) April 22, 2015 ... medical devices market witnessed tremendous growth primarily ... and increasing government support with increased nanotechnology ... , Request Customization: , http://www.marketsandmarkets.com/requestCustomization.asp?id=65048077 ... medical devices market is segmented on the ...
Breaking Biology Technology:Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries 2Nanotechnology-based Medical Devices Market to Reach Around $8.5 billion by 2019 - Published by MarketsandMarkets 2Nanotechnology-based Medical Devices Market to Reach Around $8.5 billion by 2019 - Published by MarketsandMarkets 3
... 11 Altogen Biosystems,( http://www.altogen.com ) announced ... Las Vegas, NV, Altogen Custom Services focus ... Interference (RNAi) services, generation of stably-expressing cell,lines, ... the company will draw upon their unique ...
... affordable and accessible to all researchers, HUNTSVILLE, ... that Harvard Medical School and the University of ... Each University,purchased access to whole genome human and ... and distributed by Open Biosystems., (Logo: ...
... China-based R&D and production platform and Datascope,s strong US-based ... direct sales and service network, Provides powerful ... ... SHENZHEN, China, March 11 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: ...
Cached Biology Technology:Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services 2Open Biosystems' Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina 2Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 2Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 3Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 4Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 5Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 6
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... popular designer cannabis products called "Spice" or "K2" have ... researchers is reporting progress toward understanding what makes them ... Analytical Chemistry , describes development of a method ... thousands of young adults and teens who end up ...
... for Parkinson,s Research and Shake It Up Australia Foundation ... Institute of Medical Research to look at the role ... non-coding RNAs are complex molecules, produced from a DNA ... body. Unlike conventional genes, they do not make proteins ...
... of strong design competence and cutting-edge cellulose-based technologies ... aim is for fibre from wood-based biomass to ... and polyester production, which consumes oil. A research ... Finland, Aalto University and Tampere University of Technology ...
Cached Biology News:Garvan Institute receives grant to research role of long non-coding RNAs in Parkinson's disease 2Finland to lead the way as a designer of cellulose-based products 2Finland to lead the way as a designer of cellulose-based products 3
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
... Kinase. This product is expected ... other mammalian species but has not ... a single precipitin line against partially ... shown to react with all forms ...
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... tube handling and reagent dispensing Holds: ... - 96 x 0.3ml U-bottom Omnistrips ... Non-Skirted Plate - Thermo-Fast® 96 Semi-Skirted Plate ... Multiple workstations can be securely stacked Can be stored ...
Biology Products: